N0289

Nafamostat mesylate

≥98% (HPLC), powder, serine protease inhibitor

• Synonyme(s) : 4-[(Aminoiminomethyl)amino]benzoic acid 6-(aminoiminomethyl)-2-naphthalenyl ester dimethanesulfonate, FUT-175
• Formule empirique (notation de Hill) : C₁₉H₁₇N₅O₂ · 2CH₄O₃S
• Numéro CAS: 82956-11-4
• Poids moléculaire : 539.58
• UNSPSC Code: 51111800
• PubChem Substance ID: 329818423
• NACRES: NA.77
• MDL number: MFCD00941430
• Assay: ≥98% (HPLC)
• Form: powder

Propriétés

• Nom du produit: Nafamostat mesylate, ≥98% (HPLC)
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 10 mg/mL, clear, H₂O: >10 mg/mL
• storage temp.: room temp
• SMILES string: CS(O)(=O)=O.CS(O)(=O)=O.NC(=N)Nc1ccc(cc1)C(=O)Oc2ccc3cc(ccc3c2)C(N)=N
• InChI: 1S/C19H17N5O2.2CH4O3S/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23;2*1-5(2,3)4/h1-10H,(H3,20,21)(H4,22,23,24);2*1H3,(H,2,3,4)
• InChI key: SRXKIZXIRHMPFW-UHFFFAOYSA-N

Description

Application

Nafamostat mesylate has been used:

• as a serine protease inhibitor to study its effects on proteolytic degradation of therapeutic proteins recombinantly expressed in Chinese hamster ovary (CHO)-K1-derived cells
• to stop complement activation to validate the assay for murine C3 fragments
• as a serine protease inhibitor to study its effects on house dust mite extract evoked Ca²⁺ entry

Biochem/physiol Actions

Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation.

Nafamostat mesylate is a broad spectrum serine protease inhibitor, kallikrein inhibitor, and inhibits blood coagulation. It is also a possible complement inhibitor.

Nafamostat mesylate is used in the treatment of disseminated intravascular coagulation (DIC), pancreatitis, and systemic inflammatory response syndrome. It can block the proliferation, adhesion, and invasion of cancer cells and repress tumor progression in animal models. Nafamostat mesylate is involved in the development of immune activity. In combination with favipiravir, nafamostat mesylate may block virus entry and replication, and inhibit the pathogenic host response. This combination treatment might be effective for critically ill Covid-19 patients.

Informations sur la sécurité

• pictograms: GHS08
• signalword: Warning
• hcodes: H361fd
• pcodes: P201 - P202 - P280 - P308 + P313 - P405 - P501
• Hazard Classifications: Repr. 2
• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)